LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In First Choice Healthcare Solutions, Inc. To Contact The Firm

    Reading Time: 2 minutes

    NEW YORK–(BUSINESS WIRE)–Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
    investors in First Choice Healthcare Solutions, Inc. (“First Choice” or
    the “Company”)(Other OTC:FCHS) of the May 28, 2019 deadline to seek the
    role of lead plaintiff in a federal securities class action that has
    been filed against the Company.

    If you invested in First Choice stock or options between April 1,
    2014 and November 14, 2018
    and would like to discuss your legal
    rights, click here: www.faruqilaw.com/FCHS.
    There is no cost or obligation to you.

    You can also contact us by calling Richard Gonnello toll free at 877-247-4292
    or at 212-983-9330 or by sending an e-mail to [email protected].

    The lawsuit has been filed in the U.S. District Court for the Middle
    District of Florida on behalf of all those who purchased First Choice
    common stock between April 1, 2014 and November 14, 2018 (the “Class
    Period”). The case, Maz Partners LP v. First Choice Healthcare
    Solutions, Inc. et al.
    , No. 6:19-cv-00619 was filed on March 29,
    2019 and has been assigned to Judge Paul G. Byron.

    The lawsuit focuses on whether the Company and its executives violated
    federal securities laws by failing to disclose their involvement in a
    pump and dump scheme that manipulated and artificially inflated the
    price of First Choice common stock, rendering certain of their public
    statements materially misleading.

    On November 14, 2018, the DOJ filed its criminal indictment against
    Romandetti and his co-conspirators. On November 15, 2018, the DOJ issued
    a press release announcing the indictment and that it had charged
    Romandetti “and his associates Frank Sarro, Jeffrey Miller, and Mark
    Burnett with conducting a pump and dump scheme in coordination with
    Elite Stock Research (ESR), a boiler room, to defraud investors in
    FCHS…. The charges include conspiracies to commit securities fraud,
    wire fraud and money laundering, and substantive securities fraud.”

    That same day, the SEC filed a complaint and issued a press release
    announcing its charges “for defrauding elderly and unsophisticated
    investors.” The SEC alleged that Romandetti, Elite Stock Research, Mark
    Burnett, Jeffrey Miller, Anthony Vassallo and Frank Sarro, manipulated
    First Choice’s “shares generating more than $3.3 million of illegal
    profits and more than $560,000 in kickbacks for Romandetti.”

    On this news, First Choice’s share price fell from $1.01 per share on
    November 14, 2018 to a closing price of $0.35 on November 15, 2018: a
    $0.66 or a 65.35% drop.

    The court-appointed lead plaintiff is the investor with the largest
    financial interest in the relief sought by the class who is adequate and
    typical of class members who directs and oversees the litigation on
    behalf of the putative class. Any member of the putative class may move
    the Court to serve as lead plaintiff through counsel of their choice, or
    may choose to do nothing and remain an absent class member. Your ability
    to share in any recovery is not affected by the decision to serve as a
    lead plaintiff or not.

    Faruqi & Faruqi, LLP also encourages anyone with information regarding
    First Choice’s conduct to contact the firm, including whistleblowers,
    former employees, shareholders and others.

    Attorney Advertising. The law firm responsible for this advertisement is
    Faruqi & Faruqi, LLP (www.faruqilaw.com).
    Prior results do not guarantee or predict a similar outcome with respect
    to any future matter. We welcome the opportunity to discuss your
    particular case. All communications will be treated in a confidential


    685 Third Avenue, 26th Floor
    York, NY 10017
    Attn: Richard Gonnello, Esq.
    [email protected]
    (877) 247-4292 or (212) 983-9330